123 related articles for article (PubMed ID: 4044343)
1. External beam pelvic radiotherapy plus intraperitoneal radioactive chronic phosphate in early stage ovarian cancer: a toxic combination. A National Cancer Institute of Canada Clinical Trials Group Report.
Klaassen D; Starreveld A; Shelly W; Miller A; Boyes D; Gerulath A; Levitt M
Int J Radiat Oncol Biol Phys; 1985 Oct; 11(10):1801-4. PubMed ID: 4044343
[TBL] [Abstract][Full Text] [Related]
2. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report.
Klaassen D; Shelley W; Starreveld A; Kirk M; Boyes D; Gerulath A; Levitt M; Fraser R; Carmichael J; Methot Y
J Clin Oncol; 1988 Aug; 6(8):1254-63. PubMed ID: 3045264
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal radioactive chromic phosphate P 32 in the treatment of ovarian cancer.
Powell JL; Burrell MO; Kirchner AB
South Med J; 1987 Dec; 80(12):1513-7. PubMed ID: 3423895
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal radioactive chromic phosphate (P32) in the treatment of ovarian cancer.
Powell JL; Kirchner AB
J Med Assoc Ga; 1984 Jan; 73(1):21-5. PubMed ID: 6707541
[No Abstract] [Full Text] [Related]
5. Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications.
Walton LA; Yadusky A; Rubinstein L
Int J Radiat Oncol Biol Phys; 1991 May; 20(5):939-44. PubMed ID: 2022522
[TBL] [Abstract][Full Text] [Related]
6. Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada--Clinical Trials Group (NCIC-CTG).
Dent SF; Klaassen D; Pater JL; Zee B; Whitehead M
Ann Oncol; 2000 Jan; 11(1):65-8. PubMed ID: 10690389
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging.
Soper JT; Wilkinson RH; Bandy LC; Clarke-Pearson DL; Creasman WT
Am J Obstet Gynecol; 1987 May; 156(5):1153-8. PubMed ID: 3578429
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.
Potter ME; Partridge EE; Shingleton HM; Soong SJ; Kim RY; Hatch KD; Austin JM
Gynecol Oncol; 1989 Mar; 32(3):314-8. PubMed ID: 2920951
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer.
Varia M; Rosenman J; Venkatraman S; Askin F; Fowler W; Walton L; Halle J; Currie J
Cancer; 1988 Mar; 61(5):919-27. PubMed ID: 3338057
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant intraperitoneal chromic phosphate therapy in a woman with early ovarian carcinoma and pelvic infection with resulting catastrophic complications.
McGowan L
Clin Nucl Med; 1994 Aug; 19(8):696-8. PubMed ID: 7955749
[TBL] [Abstract][Full Text] [Related]
11. Ovarian carcinoma: adjuvant treatment with P-32.
Reddy S; Sutton GP; Stehman FB; Hornback NB; Ehrlich CE
Radiology; 1987 Oct; 165(1):275-8. PubMed ID: 3628782
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma.
Soper JT; Creasman WT; Clarke-Pearson DL; Sullivan DC; Vergadoro F; Johnston WW
Am J Obstet Gynecol; 1985 Sep; 153(2):191-6. PubMed ID: 4037013
[TBL] [Abstract][Full Text] [Related]
13. Five and ten year estimated survival and disease-free rates after intraperitoneal chromic phosphate; stage I ovarian adenocarcinoma.
Piver MS; Lele SB; Bakshi S; Parthasarathy KL; Emrich LJ
Am J Clin Oncol; 1988 Oct; 11(5):515-9. PubMed ID: 3177251
[TBL] [Abstract][Full Text] [Related]
14. Radioactivity in blood and urine following intraperitoneal instillation of chromic phosphate in patients with and without ascites.
Bakri YN; Given FT
Am J Obstet Gynecol; 1984 Sep; 150(2):184-8. PubMed ID: 6476040
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.
Soper JT; Berchuck A; Clarke-Pearson DL
Cancer; 1991 Aug; 68(4):725-9. PubMed ID: 1855171
[TBL] [Abstract][Full Text] [Related]
16. Distribution and tissue dose of intraperitoneally administered radioactive chromic phosphate (32P) in New Zealand white rabbits.
Leichner PK; Rosenshein NB; Leibel SA; Order SE
Radiology; 1980 Mar; 134(3):729-34. PubMed ID: 7355227
[TBL] [Abstract][Full Text] [Related]
17. Pleuroperitoneal migration of intraperitoneal phosphorus-32-chromic phosphate therapy for stage I ovarian carcinoma.
Wilkinson RH
J Nucl Med; 1996 Apr; 37(4):636-9. PubMed ID: 8691256
[TBL] [Abstract][Full Text] [Related]
18. Phosphorus-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy.
Pattillo RA; Collier BD; Abdel-Dayem H; Ozker K; Wilson C; Ruckert AC; Hamilton K
J Nucl Med; 1995 Jan; 36(1):29-36. PubMed ID: 7799078
[TBL] [Abstract][Full Text] [Related]
19. Intracavitary chromic phosphate (32P) colloidal suspension therapy.
Jackson GL; Blosser NM
Cancer; 1981 Dec; 48(12):2596-8. PubMed ID: 7306919
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.
Varia MA; Stehman FB; Bundy BN; Benda JA; Clarke-Pearson DL; Alvarez RD; Long HJ;
J Clin Oncol; 2003 Aug; 21(15):2849-55. PubMed ID: 12885800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
